Sanofi (SNY) Unit Says MACI Met Co-Primary Endpoint vs. Microfracture in Phase 3 Trial

Go back to Sanofi (SNY) Unit Says MACI Met Co-Primary Endpoint vs. Microfracture in Phase 3 Trial